Brokerages Set Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Target Price at $43.71

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) has earned a consensus rating of “Moderate Buy” from the ten ratings firms that are covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a sell rating, six have given a buy rating and two have given a strong buy rating to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $43.7143.

Several equities analysts recently weighed in on CRBP shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Corbus Pharmaceuticals in a research report on Wednesday, January 21st. Oppenheimer boosted their price objective on Corbus Pharmaceuticals from $53.00 to $57.00 and gave the stock an “outperform” rating in a report on Tuesday, March 10th. Finally, Jefferies Financial Group raised Corbus Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, February 18th.

Insider Transactions at Corbus Pharmaceuticals

In related news, insider Dominic Smethurst sold 3,285 shares of the stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $8.09, for a total value of $26,575.65. Following the completion of the sale, the insider directly owned 95,887 shares of the company’s stock, valued at approximately $775,725.83. This represents a 3.31% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 3.60% of the company’s stock.

Institutional Trading of Corbus Pharmaceuticals

Institutional investors have recently made changes to their positions in the company. Velan Capital Investment Management LP raised its holdings in shares of Corbus Pharmaceuticals by 3.4% in the third quarter. Velan Capital Investment Management LP now owns 61,000 shares of the biopharmaceutical company’s stock valued at $772,000 after purchasing an additional 2,000 shares during the last quarter. Mariner LLC boosted its holdings in Corbus Pharmaceuticals by 34.0% during the third quarter. Mariner LLC now owns 20,840 shares of the biopharmaceutical company’s stock worth $264,000 after purchasing an additional 5,289 shares during the last quarter. Persistent Asset Partners Ltd purchased a new position in Corbus Pharmaceuticals during the fourth quarter worth about $54,000. ADAR1 Capital Management LLC bought a new stake in Corbus Pharmaceuticals in the 3rd quarter worth about $129,000. Finally, Virtu Financial LLC bought a new stake in Corbus Pharmaceuticals in the 4th quarter worth about $88,000. Institutional investors own 64.64% of the company’s stock.

Corbus Pharmaceuticals Trading Down 6.0%

CRBP opened at $9.05 on Friday. Corbus Pharmaceuticals has a 1-year low of $4.64 and a 1-year high of $20.56. The company has a market cap of $160.55 million, a price-to-earnings ratio of -1.51 and a beta of 2.84. The company’s fifty day moving average price is $8.38 and its two-hundred day moving average price is $10.52.

Corbus Pharmaceuticals (NASDAQ:CRBP) last issued its quarterly earnings data on Monday, March 9th. The biopharmaceutical company reported ($1.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.78) by $0.53. As a group, equities analysts forecast that Corbus Pharmaceuticals will post -4.23 earnings per share for the current fiscal year.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of therapeutic candidates for rare, life-threatening inflammatory and fibrotic diseases. The company’s lead investigational therapy, lenabasum, is a synthetic, oral cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation by harnessing the body’s innate resolution pathways. Corbus operates by advancing small-molecule compounds through preclinical and clinical studies to address unmet medical needs in autoimmune and inflammatory disorders.

Lenabasum is currently under evaluation in a Phase 3 clinical trial for diffuse cutaneous systemic sclerosis (dcSSc) and in a Phase 2 study for cystic fibrosis–related inflammation.